| Literature DB >> 30266736 |
Jamie J Kirkham1, Douglas G Altman2, An-Wen Chan3, Carrol Gamble4, Kerry M Dwan5, Paula R Williamson4.
Abstract
Entities:
Mesh:
Year: 2018 PMID: 30266736 PMCID: PMC6161807 DOI: 10.1136/bmj.k3802
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Fig 1Outcome matrix for review on topiramate add-on use for drug resistant partial epilepsy, with letters indicating ORBIT (Outcome Reporting Bias In Trials) classifications
The ORBIT (Outcome Reporting Bias In Trials) classification system for missing or incomplete outcome reporting in benefit outcomes. Figure 1 uses these classifications5
| ORBIT classification | Description | Level of reporting | Risk of bias* |
|---|---|---|---|
| Clear that the outcome was measured and analysed | |||
| A | Trial report states that outcome was analysed but only reports that result was not significant (typically stating P>0.05) | Partial | High risk |
| B | Trial report states that outcome was analysed but only reports that result was significant (typically stating P<0.05) | Partial | No risk |
| C | Trial report states that outcome was analysed but insufficient data were presented for the trial to be included in meta-analysis or to be considered to be fully tabulated | Partial | Low risk |
| D | Trial report states that outcome was analysed but no results reported | None | High risk |
| Clear that the outcome was measured | |||
| E | Clear that the outcome was measured. Judgment says outcome likely to have been analysed but not reported because of non-significant results | None | High risk |
| F | Clear that the outcome was measured. Judgment says outcome unlikely to have been analysed | None | Low risk |
| Unclear whether the outcome was measured | |||
| G | Not mentioned but clinical judgment says likely to have been measured and analysed but not reported on the basis of non-significant results | None | High risk |
| H | Not mentioned but clinical judgment says unlikely to have been measured at all | None | Low risk |
| Clear that the outcome was not measured | |||
| I | Clear that the outcome was not measured | NA | No risk |
NA=not appropriate.
Risk of bias arising from the lack of inclusion of non-significant results when a trial was excluded from a meta-analysis or not fully reported in a review because the data were unavailable.
The ORBIT II (Outcome Reporting Bias In Trials II) classification system for missing or incomplete outcome reporting in harm outcomes. Figure 1 uses these classifications6
| ORBIT II classification | Description | Level of reporting | Risk of bias* |
|---|---|---|---|
| Explicit specific harm outcome: measured and compared across treatment groups | |||
| P1 | States outcome analysed but reported only that P>0.05 | Partial | High risk |
| P2 | States outcome analysed but reported only that P<0.05 | Partial | High risk |
| P3 | Insufficient reporting for meta-analysis or full tabulation | Partial | Low risk |
| Explicit specific harm outcome: measured but not compared across treatment groups | |||
| Q | Clear that outcome was measured and clear outcome was not compared | NA | No risk |
| Explicit specific harm outcome: measured, not clear whether compared or not across treatment groups | |||
| R1 | Clear that outcome was measured but no results reported | None | High risk |
| R2 | Result reported globally across all groups | None | High risk |
| R3 | Result reported from some groups only | None | High risk |
| Specific harm outcome not explicitly mentioned: clinical judgment says likely measured and likely compared across treatment groups | |||
| S1 | Only pooled adverse events reported (could include specific harm outcome) | None | High risk |
| S2 | No harms mentioned or reported | None | High risk |
| Specific harm outcome not explicitly mentioned: clinical judgment says likely measured but no events | |||
| T1 | Specific harm not mentioned but all other specific harms fully reported | None | Low risk |
| T2 | No description of specific harms | None | Low risk |
| Specific harm outcome not explicitly mentioned, clinical judgment says unlikely measured | |||
| U | No harms mentioned or reported | None | Low risk |
| Explicit the specific harm outcome was not measured | |||
| V | Report clearly specifies that data on the specific harm of interest were not measured | NA | No risk |
NA=not appropriate.
Bias would occur if specific harm had been measured, but data were presented or suppressed in a way that would mask the harm profile of particular interventions.
Risk assessment of add-on use of topiramate for drug resistant partial epilepsy, accounting for partially reported and unreported study outcomes. Data are Mantel-Haenszel estimates and confidence intervals, unadjusted and adjusted for outcome reporting bias (using the Copas method)16
| Outcome | Pooled estimate, relative risk (95% CI) | |
|---|---|---|
| Unadjusted | Copas adjustment | |
| Benefits | ||
| 50% seizure reduction | 2.97 (2.38 to 3.72) | 2.87 (2.31 to 3.57) |
| Seizure freedom | 3.41 (1.37 to 8.51) | 2.66 (1.19 to 5.78) |
| Harms | ||
| Treatment withdrawal | 2.44 (1.45 to 4.10) | 2.47 (1.48 to 4.13) |
| Dizziness | 1.54 (1.07 to 2.22) | 1.64 (1.16 to 2.32) |
| Headache | 0.99 (0.67 to 1.44) | 1.14 (0.83 to 1.58) |
| Nausea and vomiting | 1.50 (0.71 to 3.15) | 1.90 (1.08 to 3.59) |
| Paraesthesias | 3.91 (1.51 to 10.12) | 4.40 (1.87 to 10.83) |
| Weight loss | 3.47 (1.55 to 7.79) | 3.60 (1.69 to 7.92) |
| Fatigue | 2.19 (1.42 to 3.40) | 2.22 (1.46 to 3.42) |
| Somnolence | 2.29 (1.49 to 3.51) | 2.35 (1.55 to 3.57) |
| Concentration impairment | 7.81 (2.08 to 29.29) | 8.25 (2.45 to 29.89) |
| Speech difficulty | 3.37 (0.80 to 14.13) | 4.48 (1.55 to 16.01) |
| Thinking abnormality | 5.70 (2.26 to 14.38) | 6.02 (2.54 to 14.79) |
| Ataxia | 2.29 (1.10 to 4.77) | 2.61 (1.36 to 5.16) |